Actualités

A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Management attributed the quarter’s performance to strong partner-driven revenue streams, particularly from milestone payments and supply sales tied to agreements with Sanofi and Pfizer. CEO John Jacobs emphasized the shift from direct commercial activity to a strategy anchored by licensing and collaboration, noting, “We now have either licensing

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In early May 2026, Novavax reported first-quarter revenue of US$139.51 million versus US$666.66 million a year earlier, swinging from net income of US$518.65 million to a net loss of US$9.49 million and posting basic and diluted loss per share of US$0.06 from continuing operations. Despite the year-on-year drop in sales and profitability, Novavax’s quarterly results exceeded market expectations and were underpinned by new Matrix-M licensing activity, including an upfront US$30 million...

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the day's top trending stock tickers, including memory chip stocks Micron Technology (MU), Intel (INTC), and Qualcomm (QCOM) opening at record highs; shares of Moderna (MRNA) and Novavax (NVAX) reacting to concerns around the hantavirus; and Constellation Energy (CEG) affirming its full-year guidance after beating first quarter earnings estimates.

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer. The rally is outpacing fellow vaccine names Pfizer (NYSE:PFE), up 2% near $26.10, and Novavax (NASDAQ:NVAX), basically flat ... Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Although a better-than-expected Q1 earnings print has NVAX stock skyrocketing recently, there’s a high risk in chasing this biotech play.

The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.

Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.

Companies in The News Are: DIS,NVAX,MAR,BWA

Unknown Executive: Good morning, and thank you all for joining us today to discuss our third quarter 2025 financial results and operational highlights. Each forward-looking statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements.

Moby summary of Novavax, Inc.'s Q1 2026 earnings call

Novavax (NASDAQ:NVAX) executives used the company’s first-quarter 2026 earnings call to highlight continued progress in reshaping the business around partner-driven revenue, a leaner operating model, and selective internal R&D designed to seed additional collaborations. Strategy centered on par

James Kelly: Good morning, and thank you for joining us today to discuss our first quarter 2026 financial results and operational highlights. The forward-looking statements in this presentation are only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.

Luis Sanay: Good morning, and thank you all for joining us today to discuss our second quarter 2025 financial results and operational highlights. Before we begin with prepared remarks, I need to remind you that this presentation includes forward-looking statements, including, but not limited to, statements related to Novavax's corporate strategy and operating plans, its strategic priorities, its partnerships and expectations with respect to potential royalties, milestones and cost reimbursements, its expectations regarding manufacturing capacity, timing, production and delivery for its COVID-19 vaccine, the development of Novavax's clinical and preclinical product candidates, the timing and results of our clinical trials, including the Nuvaxovid post-marketing commitment study, full year 2025 financial guidance and revenue framework and Novavax's future financial or business performance.

Novavax (NVAX) delivered earnings and revenue surprises of +75.68% and +100.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 79.1% year on year to $139.5 million. Its GAAP loss of $0.06 per share was 73.5% above analysts’ consensus estimates.

ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.